Abstract
Objective: This study aimed to determine the relationship between tosilizumab use and eosinophil counts in patients with rheumatoid arthritis. Material and Methods: Thirty five patients diagnosed with rheumatoid arthritis (RA) receiving either synthetic disease-modifying antirheumatic drugs (DMARDs) or tocilizumab treatment were included in this study. Patient age and disease duration, disease activity parameters and eosinophil values were recorded. Results: Comparing the eosinophil counts and percentages of the DMARD group with the Tocilizumab group, any statistically significant differences were found. There was no significant difference in eosinophil counts and percentages in the DMARD group in repeated measurements. However, in the Tocilizumab group, there was a significant difference in both parameters. Conclusion: A significant increase in eosinophil counts was observed in the group receiving tocilizumab therapy at the 1st month. Therefore, during treatment monitoring, especially in the early stages, attention should also be paid to eosinophil values.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call